[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrophy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054284","early-phase-1-metformin-and-aclr-muscle-recovery-100054284",false,"NCT07699367","Metformin and ACLR Muscle Recovery","Metformin and Muscle Recovery Following ACL Surgery","Inclusion Criteria:\n\n1. Age between 40y and older\n2. BMI: \\\u003C30 kg\u002Fm2\n3. Full thickness ACL tear\n4. Less than 6 months between ACL injury and scheduled ACLR\n\nExclusion Criteria:\n\n1. Prior ACL tear in limb scheduled for reconstruction or current bilateral ACL tear\n2. Total knee dislocation\n3. Anticipated quadriceps ACLR grafts\n4. Current infection near the lower limb\n5. Inability to attend physical therapy sessions\n6. Post-operative loading restrictions\n7. History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)\n8. History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes (Treated hypo\u002Fhyperthyroid for at least 6 months will be permitted)\n9. History of stroke with motor disability\n10. History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n11. Self-reported pregnancy\n12. Bleeding disorder\n13. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n14. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n15. Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids will be permitted)\n16. Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement will be permitted)\n17. Currently taking estrogen products (topical estrogen products will be permitted)\n18. Taking anticoagulant medication (warfarin\u002FCoumadin, heparin) that may complicate the muscle biopsy\n19. Any staff members who report directly to the principal investigators","ALL","40 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The purpose of this research study is to determine if Metformin taken after anterior cruciate ligament reconstruction (ACLR) surgery can decrease muscle fibrosis, cellular senescence and improve leg strength. ACL injury and surgery increase muscle collagen content and inflammation which slows the recovery of muscle and function and ultimately impacts the quality of life. Individuals enrolled in the study will be randomized to receive metformin (or placebo) for 4 months after surgery. The investigators will measure muscle strength and inflammatory markers in muscle biopsy samples after the intervention period. Investigators will also follow up with participants 8 months later to determine the lasting effects of the intervention.",[26,27,28],"Atrophy","Inflammation","Weakness, Muscle","NOT_YET_RECRUITING","2026-07-09",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-11-01",{"date":37,"type":20},"2032-10-01",{"name":39,"class":40},"University of Utah","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100506086","phase-2-influence-of--hydroxy--methyl-butyrate-hmbsupplementation-on-post-operative-muscle-mass-and-function-in-female-athletes-100506086","NCT05869812","Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes","FAKS-HMB","Inclusion Criteria:\n\n1. Participant has provided written and dated informed consent to participate in the study.\n2. Participant is biological female between 18 and 45 years of age, inclusive.\n3. Participant intends to complete postoperative rehabilitation at affiliated physical therapy clinic.\n\nExclusion Criteria:\n\n1. Participant is currently consuming nutritional supplements or has recently (regularly) consumed nutritional supplements, other than multivitamins and minerals in \\\u003C9 weeks prior to participation.\n2. Participant currently suffers from a sleep disorder and\u002For has a known history of (or is currently being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might limit natural recovery from substantial injury.\n3. Participant has a history of orthopedic injury or surgery within the last year in the non-operative limb that may prevent them from completing the study procedures.\n4. Participant has history of previous injury or surgery in the operative limb.\n5. Participant has implants, hardware, devices, or other non-removable metal material in the body that would limit the accuracy of body composition assessments within the measurement area.\n6. Participant is participating in another clinical trial or has received an investigational product within thirty days prior to enrollment.\n7. Participant has a known allergy or sensitivity to any ingredient in the test product\u002Fs.\n8. Participant is pregnant as confirmed by a urine sample and hCG test.","FEMALE","18 Years","45 Years",{"count":53,"type":20},30,[55],"PHASE2","The proposed project will evaluate the musculoskeletal outcomes of quadriceps and hamstring muscle size and function following orthopedic knee surgery involving anterior cruciate ligament (ACL) repair or reconstruction. Currently, the research team collaborates with a team of orthopedic specialists at the University of Kansas Health System and monitor muscle size post-knee repair and follow the standard of care (SOC) practices of the licensed physical therapists (PT). The proposed project will include a randomized clinical trial to observe the muscular outcomes following the current SOC plus supplementation of calcium-β-hydroxy-β-methylbutyrate (caHMB) or placebo. CaHMB has been shown to improve rates of muscle protein synthesis while suppressing muscle protein breakdown in healthy adults. The use of caHMB has also provided evidence of muscular protection from atrophy during prolonged bed rest. This evidence supports the utility in clinically injured athletes that are subjected to disuse atrophy from the inability to bear weight or participate in typical daily physical activity. Additionally, matched for activity-related knee injuries, female athletes are more susceptible to incurring a significant injury due to a variety of genetic, hormonal, biological, anatomical, and biomechanical predispositions. Therefore, the proposed study will recruit approximately 30 females over the age of 18 that have sustained an injury to the ACL and will plan to undergo reconstructive knee surgery involving the ACL. Subjects will be monitored and measured prior to their surgical date (T0), at 2-weeks post operative (T1), and every 6-weeks until they are cleared to return to sport (T2-TRTS). Participants will be randomly assigned 1:1 in a double-blind manner to either an experimental (EXPHMB) or placebo (CONPLA) group. Doses will be provided to the participants in coded containers and will complete their dosing and a record log of intake for the duration of their rehabilitation. Three 3-day food, exercise, and health record logs will be collected to monitor nutritional intake, activity, and menstrual patterns at T0, T3, and TRTS. Participant's assessments will include body composition analysis via bioelectrical impedance analysis for total and segmental muscle and fat mass, skeletal muscle mass, and body fat percent. We will collect ultrasound images of the quadriceps and hamstrings of the operative-involved limb (OPIL) and non-operative limb (NOPL) limbs for muscle cross-sectional area (mCSA), thickness (mT), subcutaneous fat thickness (TFAT), and corrected echo intensity (EICOR) at all time points. Strength and functional assessments will occur upon entrance to the study (T0), and after loaded exercise is indicated by the practitioner (T3-TRTS) to the tolerance of the athlete. These assessments include maximal voluntary isometric contractions (MVIC) for leg extension and leg curl, standing balance tests, single-leg and double-leg jump assessment, and drop landing deviation, all on dual force plates. Data will be analyzed using multiple three-way analyses of variance \\[surgical leg (OPIL vs. NOPL) x treatment (EXPHMB vs. CONPLA) x time (T0 vs. T1 vs. T2 vs. T3 vs. T4 vs. T5 vs. TRTS) for the dependent variables. Significance is established at p≤0.05 and follow-up ANOVAS, T-tests, and post-hoc analyses will be conducted when significance is present. The evidence from this study will support the practitioners and coaches' abilities to maximize recovery and training outcomes, respectively, in previously injured female athletes.",[26],[59],"musculoskeletal","RECRUITING","2026-02-26",{"date":63,"type":33},"2026-03-02",{"date":65,"type":33},"2023-05-29",{"date":67,"type":20},"2029-12",{"name":69,"class":40},"University of Kansas Medical Center",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100593122","investigation-of-respiratory-muscle-sarcopenia-in-adults-diagnosed-with-diabetes-100593122","NCT07002333","Investigation of Respiratory Muscle Sarcopenia in Adults Diagnosed With Diabetes","Inclusion Criteria:\n\n* Age between 18-65\n* Diagnosed with Type 2 Diabetes mellitus\n* Being clinically stable\n* Ability to adapt to tests (visual, cognitive, cooperative)\n\nExclusion Criteria:\n\n* Those with neurological and\u002For musculoskeletal problems that may affect the study\n* Presence of severe joint contracture or painful ulcers that may affect muscle strength measurement and walking\n* Presence of serious infection or sepsis\n* Having a known additional rheumatological disease diagnosis\n* Any stage of cancer\n* Pregnant or breastfeeding women","65 Years",{"count":78,"type":20},85,"OBSERVATIONAL","The aim of this study was to investigate respiratory muscle sarcopenia in individuals with diabet. The main question it aims to answer is:\n\nWhat is the prevalence of respiratory muscle sarcopenia in patients with diabet? Participants body composition (bioelectrical impedance), hand grip strength (hand dynanometer), physical performance tests (5 repetition sit-and-stand test, 4-meter walk test, 6 minute walk test, Timed up-and-go test) and respiratory muscle strength were evaluated.",[82,83,84,26],"Diabetes","Diabetes Mellitus","Sarcopenia","2025-06-02",{"date":87,"type":33},"2025-06-03",{"date":89,"type":20},"2025-07",{"date":91,"type":20},"2025-10",{"name":93,"class":40},"Kirsehir Ahi Evran Universitesi",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":4,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":100,"sex":16,"minAge":50,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100219730","a-modified-sinus-floor-elevation-technique---a-pilot-study-on-12-patients-100219730","NCT02137824","A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients","Inclusion Criteria:\n\n* residual bone height of 3-6mm\n* residual bone width of \\>4mm\n\nExclusion Criteria:\n\n* not treated periodontal disease\n* smoker (\\>5cig\u002Fday)\n* acute or chronic sinusitis",true,"100 Years",{"count":103,"type":20},12,[105],"NA","The aim of the present study is to establish a modified minimally invasive surgical technique for sinus floor augmentation with a residual bone height of 3-6mm.\n\nHypothesis: The investigators expect that the present surgical technique allows to achieve an adequate implant bed of at least 10mm height after a healing period of 3-5 months. Further the modification of the technique enables a reduced patient stress level.",[108,26],"Maxillary Sinus","2023-03-14",{"date":111,"type":33},"2023-03-15",{"date":113,"type":4},"2014-05",{"date":115,"type":20},"2030-12",{"name":117,"class":40},"Medical University of Vienna"]